Cronos Group Inc

CRON: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$8.70SkpbcQchnkfp

Cronos Remains Years Away From Positive Adjusted EBITDA, but Remains Buoyed by a Hefty Cash Balance

Business Strategy and Outlook

Cronos Group cultivates and sells cannabis predominantly in Canada and hemp-derived CBD in the U.S. but also participates in the global medical cannabis market.

Sponsor Center